Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORTD-1 in Rheumatoid Arthritis
NCT04286789Phase 1Completed
- Sponsor
- Oryn Therapeutics
- Start
- Mar 2021
- Primary completion
- Oct 2021
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ORTD-1 in rheumatoid arthritis (RA) (4 arms), sponsored by Oryn Therapeutics. Primary endpoint: Number of patients with adverse events at 10 weeks. Started Mar 2021; status: completed.
02
Drugs
ORTD-1
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT04286789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04286789.